IONS · Ionis Pharmaceuticals Inc
$57.24
+1.37 (+2.45%)
At close · Aug 14
Market Cap
$9.51B
Shares
166.18M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Mariana Baroldi | Executive Director | $679,035 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Mariana Baroldi | Executive Director | $513,949 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Mariana Baroldi | Director, Corporate Operations | $370,238 |
| Grant Swayze | Research Associate | $68,951 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Elizabeth Hougen | Executive Vice President, Finance and Chief Financial Officer | $4,128,329 |
| Patrick R. O’Neil | Executive Vice President, Chief Legal Officer and General Counsel | $3,923,145 |
| Onaiza Cadoret-Manier | Executive Vice President, Chief Global Product Strategy and Operations Officer | $3,665,966 |
| Eric Swayze | Executive Vice President, Research | $3,619,450 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Elizabeth Hougen | Executive Vice President, Finance and Chief Financial Officer | $4,341,100 |
| Patrick R. O’Neil | Executive Vice President, Chief Legal Officer and General Counsel | $3,965,065 |
| Onaiza Cadoret-Manier | Executive Vice President, Chief Global Product Strategy and Operations Officer | $3,504,442 |
| Eric Swayze | Executive Vice President, Research | $2,342,700 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Brett Monia | President, Chief Executive Officer | $6,527,963 |
| Elizabeth Hougen | Executive Vice President, Finance and Chief Financial Officer | $3,481,858 |
| Patrick R. O’Neil | Executive Vice President, Chief Legal Officer and General Counsel | $3,463,901 |
| Eric Swayze | Executive Vice President, Research | $2,112,032 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Peter N. Reikes | member of the Company's Board | Appointed | 2026-06-08 |
| Ludwig N. Hantson | member of the Company's Board | Appointed | 2026-06-08 |
| Peter N. Reikes | member of the Board of Directors | Appointed | 2026-03-09 |
| Holly Kordasiewicz, Ph.D. | executive vice president and chief development officer | Appointed | 2025-06-12 |
| Richard Geary, Ph.D. | executive vice president and chief development officer | Retired | 2025-06-12 |
| Kyle Jenné | executive vice president, commercial | Appointed | 2024-02-29 |
| Michael Yang | member of the Company's Board | Appointed | 2023-12-14 |
| Frederick Muto | member of the Board of Directors | Retired | 2022-07-18 |
Key facts
CIK
874015
CUSIP
462222100
13F (30d)
498 filings
470 filers
Visit website
Investor relations